Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC FLU Quadrivalent (GC3110A) is a quadrivalent, split-virion, inactivated influenza vaccine developed by Green Cross Corporation (GC Biopharma). Produced using fertilized chicken eggs, the vaccine contains purified hemagglutinin (HA) antigens from four influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). This quadrivalent formulation is designed to provide broader protection than traditional trivalent vaccines by including a second B-lineage strain, addressing the challenge of predicting which B lineage will predominate in a given season. The vaccine is indicated for the prevention of seasonal influenza in individuals aged 6 months and older and has been approved for use in South Korea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GC FLU Quadrivalent (GC Biopharma).